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Abstract
Background: Genome wide association studies (GWAS) have identified several genetic variants that are associated 
with prostate cancer. Most of these variants, like other GWAS association signals, are located in non-coding regions of 
potential candidate genes, and thus could act at the level of the mRNA transcript.
Methods: We measured the expression and isoform usage of seven prostate cancer candidate genes in benign and 
malignant prostate by real-time PCR, and correlated these factors with cancer status and genotype at the GWAS risk 
variants.
Results: We determined that levels of LMTK2 transcripts in prostate adenocarcinomas were only 32% of those in 
benign tissues (p = 3.2 × 10-7), and that an independent effect of genotype at variant rs6465657 on LMTK2 expression in 
benign (n = 39) and malignant tissues (n = 21) was also evident (P = 0.002). We also identified that whilst HNF1B(C) and 
MSMB2 comprised the predominant isoforms in benign tissues (90% and 98% of total HNF1B or MSMB expression), 
HNF1B(B) and MSMB1 were predominant in malignant tissue (95% and 96% of total HNF1B or MSMB expression; P = 1.7 
× 10-7 and 4 × 10-4 respectively), indicating major shifts in isoform usage.
Conclusions: Our results indicate that the amount or nature of mRNA transcripts expressed from the LMTK2, HNF1B 
and MSMB candidate genes is altered in prostate cancer, and provides further evidence for a role for these genes in this 
disorder. The alterations in isoform usage we detect highlights the potential importance of alternative mRNA 
processing and moderation of mRNA stability as potentially important disease mechanisms.
Background
Cancer of the prostate is the most common male malig-
nancy in the Western world, accounting for 25% of all
male UK cancers (taken from http://info.cancerre-
searchuk.org/cancerstats). Although survival rates are
increasing, cancer of the prostate remains the second
most common cause of cancer death in UK men after
lung cancer. Several risk factors have been identified, the
main factors being age [1], family history [2] and ethnic
origin [3]. Prostate cancer is uncommon in men under 50
years old, but 80% of men aged over 80 years were found
to have cancerous cells in their prostate at the time of
death [1]. Estimates suggest that between 30 - 40% of all
early onset cases of prostate cancer (< 55yrs) are caused
by inherited factors [2], highlighting the importance of
genetics in this disorder. Early-onset prostate cancer that
aggregates in families is likely to result from the inheri-
tance of rare genetic variants that have a large impact.
Several strong risk factors have been identified from fam-
ily studies which include mutations in the ELAC2, RNA-
SEL and MSR1 genes involved in immune response [4]
and the BRCA1 and BRCA2 genes involved in the devel-
opment of breast cancer [5].
Despite increases in the understanding of the familial
forms of prostate cancer, the aetiology of the remaining
60% of cases remains unclear. The advent of genome wide
association studies (GWAS) has resulted in a dramatic
increase in the number of susceptibility loci that have
been associated with the development of prostate cancer
(table 1). Four independent studies in the Icelandic, UK
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Page 2 of 12and American populations have identified more than 20
distinct genomic locations as being implicated in suscep-
tibility to prostate cancer [6-9].
Many of the GWAS association signals identified are
located in regions of the genome that are not translated
into protein. This may indicate that the associated marker
is in close linkage disequilibrium with an uncharacterised
variant in the protein coding region, or that the func-
tional SNP may cause its effect by epigenetic or histone
modification. The other possibility is that the variant may
act at the level of the messenger RNA.
There are several mechanisms by which variants in
non-coding regions of the mRNA transcripts could affect
gene function. Firstly, if the variant lies in the promoter or
5' untranslated region of the transcript, it may interfere
with the efficiency of transcription or translation, as has
been shown to be the case for several human and rodent
genes [10-12]. Variants located within the intronic
sequences may interfere with mRNA splicing [13]. The
production of aberrant splice products has previously
been shown to be very important in the aetiology of can-
cer in general [14,15], but may contribute to the biologi-
cal heterogeneity of prostate cancer in particular [16].
Finally, polymorphisms located in the 3' untranslated
region may disrupt regulatory elements necessary for
mRNA stability, interfere with regulation of translation
by microRNAs or influence the polyadenylation dynam-
ics of the transcript [17-19].
In this series of experiments, we sought to investigate
whether the genes suggested by the GWAS for prostate
cancer were differentially expressed in malignant prostate
tissues, and whether their expression was influenced by
genotype at the GWAS risk variants. Seven genes were
selected for study (figure 1). We measured the total or
isoform specific gene expression of the JAZF1 (JAZF zinc
finger 1), CTBP2 (C-terminal binding protein 2), LMTK2
(lemur tyrosine kinase 2), SLC22A3 (solute carrier family
22 extraneuronal monoamine transporter, member 3),
MYEOV (myeloma overexpressed), MSMB (microsemi-
noprotein beta) and HNF1B (HNF homeobox 1 beta) in a
cohort of 39 non-malignant benign prostatic hyperplasia
(BPH) samples and 21 prostate adenocarcinoma samples,
and correlated gene expression with cancer status and
with the genetic variants identified in the GWAS (table
1). We demonstrate two of the eight variants are corre-
lated with gene expression levels in non-malignant pros-
tate tissues, and that the presence of adenocarcinoma is
associated with altered gene expression levels and differ-
ential expression of alternatively processed isoforms for
three of the candidate genes in prostate tissue itself.
Methods
Subject Details
The prostate samples in this study were obtained from
the Exeter tissue bank, and comprised prostate chippings
taken during routine transurethral resection of the pros-
tate (TURP). Both cancer and BPH groups originated
from a population of older men treated for urological
problems at the Royal Devon and Exeter Hospital, Exeter,
UK and were predominantly of Caucasian origin. Sam-
ples were flash frozen in liquid nitrogen upon removal,
and stored at -80°C until required. Subjects with benign
Table 1: Loci that have been identified as significant determinants of prostate cancer risk in four independent genome 
wide association studies.
Gene Location Marker MAF Post replication P value Position within gene Source
HNF1B 17q21.3 rs4430796
rs11649743
0.479
0.479
9.58 × 10-10
1.7 × 10-9
IVS2
IVS4
[7,8,34]
MSMB 10q11.2 rs10993994 0.339 8.7 × 10-29
7.31 × 10-13
5' UTR [8,9]
LMTK2 17q25.3 rs6465657 0.438 1.1 × 10-9 IVS9 [9]
SLC22A3 6q26-q27 rs9364554 0.233 5.5 × 10-10 IVS5 [9]
CTBP2 10q26.13 rs4962416 0.229 1.70 × 10-7 IVS1 [8]
MYEOV 11q13 rs10896449 0.492 1.76 × 10-9 Intergenic, 5' to gene [8]
JAZF1 7p15.2-p15.1 rs10486567 0.267 2.14 × 10-6 IVS2 [8]
MAF = minor allele frequency in the HapMap CEU population.
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Page 3 of 12prostatic hyperplasia (n = 39) had no sign of prostate
malignancy at the time the samples were taken, and none
had received a subsequent diagnosis of prostate cancer 5
years following their diagnosis of benign prostatic hyper-
plasia (BPH). The median age of the BPH cohort was 83
years (IQR 78,88) and the median age of the prostate can-
cer cohort was 83 years (IQR 76,87). BPH samples were
used as the control group for several reasons; firstly, most
males have evidence of BPH by the age of 70 or 80, so the
presence of some degree of BPH is 'normal' at the median
age at diagnosis in our prostate cancer cohort (77 yrs,
[IQR 72,82]). Truly 'normal' prostate tissue would thus
only be obtained in a much younger control cohort,
which could introduce bias. Secondly, since collection of
prostate tissue requires a surgical procedure, which
would only be undertaken in subjects with evidence of
symptoms of prostate enlargement. Even then, morpho-
logically normal tissue may harbour premalignant genetic
abnormalities that are not immediately obvious. How-
ever, we acknowledge that genetic heterogeneity between
patients and controls may influence the gene expression
from individual to individual. Prostate cancer samples (n
= 21) underwent confirmation of cancer status, histology
and Gleason scoring by dissection of the TURP chips and
subsequent histological examination of tissue from either
side of the sample used for RNA analysis. All cancer sam-
ples were classified as prostatic adenocarcinomas, of
which 57% were Gleason score 6 or 7, and 43% were Glea-
son score 8-10. Further analysis of patient case notes
revealed that 8/19 prostate cancer patients and 6/37
Benign Prostatic Hyperplasia patients had been exposed
to hormone treatment (Zoladex, Finasteride, Casodex or
Proscar).
Ethics Statement
All participants had consented to their tissue being used
in this study, and ethical approval was obtained from the
South West Research Ethics Committee. This study was
carried out according to the Declaration of Helsinki.
DNA extraction
DNA was extracted from prostate chippings using the
Qiagen DNA mini kit (Qiagen, Crawley, UK) using stan-
dard procedures on the fully automated QiaCube sample
preparation platform (Qiagen, Crawley, UK), following
manual homogenisation of tissue.
Figure 1 Schematic representation of the structure of transcripts studied here. The structure of the JAZF1, SLC22A3, LMTK2, MYEOV, MSMB, 
HNF1B and CTBP2 mRNAs are represented here, together with their RefSeq ID numbers. Exons are represented by numbered grey boxes. The black 
box represents the section of exon 3 absent from isoform HNF1B(B). The section of intronic sequence present in HNF1B(C) is indicated by a hatched 
box.
1 2 3 4 5 6 7 8 9 HNF1B(B) (NM_001165923) 
1 2 3 4 JAZF1 (NM_175061) 
1 2 3 4 5 6 7 8 9 10 SLC22A3 (NM_021977) 
1 2 3 4 5 6 7 8 9 10 11 12 13 LMTK2 (NM_014916) 
1 2 MYEOV (NM_138768) 
1 2 3 4 MSMB1 (NM_002443) 
1 2 4 MSMB2 (NM_138634) 
1 2 3 4 5 6 7 8 9 HNF1B(A) (NM_000458) 
1 2 3 4 HNF1B(C) (NM_006481)  
1b 2 3 4 75 6 9 108 11 CTBP2(3) (NM_001329)
1a 2 3 4 75 6 9 108 11 CTBP2(1) (NM_001083914)
1c 2 3 4 75 6 9 108 11 CTBP2(4) (AK290390 )
2b 4 75 6 9 108 11 CTBP2(2) (NM_022802)
Harries et al. BMC Cancer 2010, 10:315
http://www.biomedcentral.com/1471-2407/10/315
Page 4 of 12Choice of candidate genes
Seven candidate genes were identified for expression
analysis. These were chosen on several criteria. Firstly, we
chose our candidate genes on the basis that the GWAS
index SNPs were located within the gene sequence itself,
or very close to the genes in question. The linkage dis-
equilibrium blocks identified in the GWAS may contain
other genes (or variants) that may contribute to the risk of
developing prostate cancer, the majority of these are
located remotely to the association signal and do not rep-
resent better biological candidates. Secondly, all seven are
good biological candidates, having roles in cell prolifera-
tion, regulation of apoptosis or prostate development and
function. Analysis of the linkage disequilibrium structure
around the GWAS index SNPs revealed several other
candidates, but these were not analysed due to a lack of
expression in the prostate, a lack of convincing biological
evidence for a role in prostate function or the presence of
more plausible candidate genes. The remaining four sig-
nals located on chromosomes 3, 8, 19 and X were not
analysed due to the lack of an obvious candidate gene.
Genotyping
Genotyping was carried out by PCR amplification and
direct sequencing of the sequence flanking the variant in
question; primers and conditions are available on request.
Amplification reactions contained 10 μl Megamix Royal
(Microzone, Haywards Heath, UK), 10 μM primers and
50 ng DNA in a total volume of 20 μl. Sequence specific
primers for each amplicon were tagged with 5' M13 tails
to allow sequencing to be performed with a universal
M13 primer. Single-strand sequencing was carried out
using standard methods on an ABI 3730 (Applied Biosys-
tems, Warrington, UK). Sequences were compared to a
designated individual homozygous for the major allele of
the variant using Mutation Surveyor (version 3.20; Soft-
Genetics, State College, PA).
RNA extraction
RNA was extracted from prostate chippings using the
Qiagen RNAeasy kit (Qiagen, Crawley, UK) on the fully
automated QiaCube sample preparation platform (Qia-
gen, Crawley, UK), following manual homogenisation of
tissue with an additional pass through a Qiagen
Figure 2 Allele-specific expression of LMTK2 transcripts. This histogram demonstrates allele-specific differences in the expression of LMTK2 tran-
scripts bearing either the G or A allele at rs3801294, which is in perfect linkage disequilibrium (r2 = 1; D' = 1) with the index SNP rs6465657. The sample 
identity is given on the X-axis and the ratio of transcripts carrying G alleles (marking the C allele of rs6465657) relative to those carrying the A allele 
(marking the T allele at rs6465657) is given on the Y-axis. Error bars represent the interquartile range (IQR) of the measurements. The level of signifi-
cance as determined by pairwise Mann Whitney-U analyses is indicated by asterisks.
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Page 5 of 12Qiashreddder column (Qiagen, Crawley, UK) column to
shear genomic DNA. RNA samples were stored at -80°C
prior to analysis.
Reverse Transcription
Approximately 500 ng of mRNA from each sample was
treated with 1u of RNAse-free DNAse (Promega, Madi-
son, USA) for 30 minutes at 37°C followed by 65°C for 10
minutes for nuclease inactivation. Complementary DNA
(cDNA) was synthesized from mRNA using the Super-
script III VILO RT-PCR system (Invitrogen, Paisley, UK)
according to manufacturer's instructions, with an incuba-
tion temperature of 42°C and a reaction volume of 40 μl.
Quantitative real time PCR for the measurement of total or 
isoform-specific gene expression
Real-time PCR reactions using target-specific probes
were carried out in triplicate using the ABI Prism 7900
HT platform (Applied Biosystems, Warrington, UK) and
contained 5 μl TaqMan Fast Universal Mastermix (no
AMPerase) (Applied Biosystems, Warrington, UK), 0.9
μM each primer, 0.25 μM probe and 2 μl cDNA reverse
transcribed as above in a total volume of 10 μl. PCR con-
ditions were a single cycle of 95°C for 20 seconds followed
by 50 cycles of 95°C for 1 second and 60°C for 20 seconds.
Individual probe and primer sets were pre-validated off-
the-shelf assays to specific transcripts provided by
Applied Biosystems (Warrington, UK; Assay identifica-
tion numbers available on request). The relative expres-
sion level of each isoform was then determined relative to
the B2 M and GUSB transcripts by the comparative
(ΔΔCt) method [20]. The abundance of each target in
each individual was normalized to the average measure-
ment for the transcript in question across the cohort
prior to correlation of expression levels with genotype.
LMTK2 Allele-specific expression
Measurement of the relative abundance of transcripts
bearing different alleles at variant rs3801294, in perfect
linkage disequilibrium (r2 = 1; D' = 1) with the LMTK2
index SNP rs6465657, was carried out in single tube reac-
tions by allele-specific real time PCR. PCR amplicons
were generated by a common set of primers for both
alleles, but transcripts bearing different alleles were dis-
criminated by the use of allele-specific probes labelled
with different fluorochromes (6-fluorescein [6-FAM] and
VIC); probes and primers available on request. This
allows a measurement of transcript abundance that is
independent of amplification efficiency. Real-time PCR
reactions using were carried out in triplicate using the
ABI Prism 7900 HT platform (Applied Biosystems, War-
rington, UK) and contained 5 μl TaqMan Fast PCR Mas-
ter Mix, no AmpErase™ (Applied Biosystems,
Warrington, UK), 72 μM each primer and 16 μM each
probe) in a total volume of 10 μl. PCR conditions were a
single cycle of 95°C for 20 seconds followed by 60 cycles
of 95°C for 1 second and 60°C for 20 seconds. The expres-
sion level of transcripts bearing the G allele (marking the
C allele at rs6465657) was then calculated relative to that
of transcripts bearing the A allele (marking the T allele at
rs6465657) by the comparative (ΔΔCt) method [20], as
we have done for several previous studies [21,22]. Quanti-
Table 2: Total expression levels of candidate genes in non-malignant and prostate cancer tissues.
Gene Total Expression in non-malignant prostate tissues Total Expression in prostate cancer tissues Value
JAZF1 0.82 (1.7) 0.83 (0.97) 0.185
SLC22A3 1.01 (1.42) 0.48 (0.75) 0.015
LMTK2 1.10 (0.77) 0.35 (0.30) 2.4 × 10-7
MSMB 95.3 (326.3) 13.5 (90.9) 0.156
HNF1B 63.0 (106.8) 37.3 (56.0) 0.175
MYEOV 0.07 (0.15) 0.08 (0.15) 0.655
CTBP2 3.35 (2.54) 2.1 (1.6) 0.008
Gene expression levels are analysed relative to the beta 2 microglobulin (B2M) and beta glucorinidase (GUSB) genes, and normalised to the 
average value in the non-malignant samples. The interquartile range is given in parentheses. A P value of 0.007 (P = 0.05/n° of tests) was taken 
to indicate statistical significance following correction for multiple testing (7 independent tests). Statistically significant results are indicated in 
bold italic type.
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ment obtained from eleven independent DNA samples,
which should provide a known 50:50 mix of A and G-
bearing transcripts, in order to control for differences in
probing efficiencies.
Statistics
The statistical significance of apparent differences in gene
expression levels was investigated by Kruskal Wallis anal-
ysis for multiway comparisons and by Mann Whitney-U
analysis for pairwise comparisons. Non-parametric sta-
tistics were employed due to the relatively small sample
numbers and the fact that the data obtained were not
normally distributed. In the case of the association
between LMTK2 expression and cancer status, linear
regression was carried out on natural logarithmically
transformed data to allow adjustment for the effect of
genotype at rs6465657, which we found to be indepen-
dently associated with LMTK2 expression. All statistical
analyses were carried out using SPSS v15.0 (SSPS PLC,
Chicago, USA).
Results
Genotyping of GWAS risk loci in benign prostatic 
hyperplasia and prostate cancer samples
We obtained 426/480 genotypes for the 8 GWAS variants
in our cohort of 39 benign prostatic hyperplasia speci-
mens and 21 prostate adenocarcinoma samples (310 for
the BPH cohort and 116 for the cancer cohort). All three
genotypes were detected for the variants, with the excep-
tion of minor allele (C) homozygotes for rs4962416
within the CTBP2 gene, as expected given the minor
allele frequency of only 0.229 in the HapMap CEU popu-
lation.
Risk genotypes at rs6465657 and rs4962416 may be 
associated with differences in LMTK2 and CTBP2 
expression levels in benign prostatic hyperplasia samples
Analysis of potential correlations between genotype at
the GWAS association loci and isoform-specific gene
expression of nearby candidate genes revealed correla-
tions between risk genotype at the GWAS variants
rs6465657 and rs4962416 with the expression of LMTK2
and CTBP2 respectively. Individuals carrying two copies
of the protective T allele of rs6465657 expressed almost a
third less LMTK2 mRNA than did individuals carrying
one or two copies of the risk 'C' allele (0.68 [Interquartile
range [IQR] = 0.63] v/s 1.18 [IQR = 0.56]; P = 0.007). Sim-
ilarly, individuals homozygous for the 'T' allele at
rs4962416 expressed 37% less of a partially characterised
isoform of CTBP2; CTBP2(4), than did individuals with
CT genotypes (0.82 [IQR 0.83] v/s 1.31 [IQR 0.96]; P =
0.009). Although neither of these findings quite reaches
full statistical significance following adjustment for mul-
Figure 3 Expression of LMTK2 transcripts is reduced in prostate cancer. This boxplot gives the cancer status (benign prostatic hyperplasia or 
prostate adenocarcinoma) on the X-axis, and the expression of the single isoform of the LMTK2 gene relative to the endogenous controls beta-2-mi-
croglobulin (B2M) and beta-glucorinidase (GUSB) on the Y-axis. Error bars represent the interquartile range (IQR) of the measurements. The level of 
significance as determined by linear regression of natural logarithmically transformed data is indicated. Outliers are indicated by circles.
P = 2.4 X 10-7
BPH Prostate cancer
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do indicate that these genes are worthy of further study.
Allele-specific differences in the expression of LMTK2 
transcripts bearing different alleles of rs6465657
We measured the abundance of each LMTK2 allele of
rs6465657 in 17 heterozygous individuals, and deter-
mined that transcripts bearing the rs3801294 'A' allele,
which is in perfect linkage disequilibrium (r2 = 1; D' = 1)
with the protective 'T' allele at rs6465657, were signifi-
cantly less abundant in heterozygous BPH tissues than
were those carrying the 'G' allele, linked to the 'C' allele of
rs6465657. The ratio of protective 'A' alleles to risk 'G'
alleles in heterozygous individuals is 0.65 [IQR 0.12]:1
[IQR 0.33]; P = 3.3 × 10-5, figure 2), which remains statis-
tically significant after adjustment for multiple testing.
This provides further evidence for a role of LMTK2 in
determining susceptibility to prostate cancer. No correla-
tions of genotype with expression levels were noted for
the remaining isoforms of the CTBP2 gene, or any iso-
form of the JAZF1, MYEOV, SLC22A3, HNF1B or MSMB
genes in BPH tissues.
Total LMTK2 expression is altered in prostate cancer tissues 
compared with non-malignant BPH samples
We correlated expression levels at each of the loci with
prostate cancer status (table 2). We found that expression
levels of the LMTK2 gene were also inversely correlated
with the presence of prostate cancer. Tumour samples
expressed 68% less LMTK2 mRNA than did non-malig-
nant BPH samples (figure 3; relative expression levels
were 1.10 [IQR 0.77] in BPH versus 0.35 [IQR 0.30] in
prostate cancer; p = 2.4 × 10-7), after correction for the
potential effect of genotype at rs6465657. Amongst the
eight members of the prostate cancer cohort who had
exposure to antiandrogenic drugs, no effect of prior hor-
mone treatment on the expression levels of LMTK2 was
noted (0.49 [IQR 0.29) for untreated subjects versus 0.32
[IQR 0.30] in treated subjects; P = 0.270).
We also noted differences in the total expression of the
SLC22A3 and CTBP2 genes in BPH compared with pros-
tate cancer. CTBP2 and SLC22A3 mRNA levels were
reduced by 27% and 50% in prostate cancer tissues com-
pared with BPH tissues (4.2 [IQR 2.5] v/s 2.1[IQR 1.6]; P
= 0.008 for CTBP2 and 0.48 [IQR 0.75] v/s 1.01 [IQR
1.42]; P = 0.015 for SLC22A3). CTBP2(1) and CTBP2(4)
transcripts showed a trend towards lower expression in
prostate cancer subjects treated with hormone therapy
(CTBP2(1) ; (0.87 [0.40] in untreated subjects versus
0.31[IQR0.17]; p = 0.006) and CTBP2(4) transcripts
(1.01[IQR 0.99] in untreated subjects versus 0.45
[IQR0.42] in treated subjects; p = 0.006) but these results
do not reach statistical significance following adjustment
for multiple testing (P = < 0.004 for 12 independent tests).
This observation was also not noted in the BPH cohort (P
Table 3: Isoform-specific expression levels of candidate genes in non-malignant and prostate cancer tissues.
Gene Total Expression in non-malignant prostate tissues Total Expression in prostate cancer tissues value
MSMB1 1.8 (6.9) 16.2 (85.2) 4 × 10-4
MSMB2 125.3 (409.8) 0.6 (4.73) 5.8 × 10-5
HNF1B(A) 1.2 (2.7) 0.94(1.52) 0.66
HNF1B(B) 5.1 (6.8) 35.1 (52.3) 1.7 × 10-7
HNF1B(C) 51.8 (109.9) 12 (3.4) 3.9 × 10-8
CTBP2(1) 1.3 (1.11) 0.62 (0.6) 0.009
CTBP2(3) 0.62 (0.55) 0.45 (0.58) 0.127
CTBP2(4) 1.4 (0.86) 0.70 (0.73) 0.007
Gene expression levels are analysed relative to the beta 2 microglobulin (B2M) and beta glucorinidase (GUSB) genes, and normalised to the 
average value in the non-malignant samples. The interquartile range is given in parentheses. A P value of 0.006 (P = 0.05/n° of tests) was taken 
to indicate statistical significance following correction for multiple testing (8 independent tests). Statistically significant results are indicated in 
bold italic type.
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Page 8 of 12= 0.77 and 0.69 for CTBP2(1) and CTBP2(4) respectively.
No association of cancer status with expression level was
found for a control gene (SFRS protein kinase 1; SRPK1),
not known to be associated with prostate cancer in any
GWAS. We did not identify any correlations of total gene
expression with cancer status for the JAZF1, MSMB,
HNF1B, MYEOV or CTBP2 genes. No correlations with
transcript expression were noted for cancer stage
(assessed by Gleason grading of the cancer) or with expo-
sure to antiandrogenic drugs for any other transcripts
analysed in either prostate cancer or BPH cohorts.
Alterations to the relative balance of alternatively spliced 
forms of the MSMB and HNF1B genes in prostate cancer 
tissues
Although we found no differences in total HNF1B,
CTBP2 or MSMB expression between BPH and prostate
cancer cases, these genes are alternatively processed. We
therefore sought to determine if there were differences in
the relative balance of isoforms within our sample cohort
(table 3). We found highly significant disturbances to the
profile of isoforms expressed in prostate cancer in the
case of the MSMB and HNF1B genes. In BPH tissues, the
primary isoform expressed at the MSMB locus is
MSMB2, which comprises 98% of MSMB expression in
this tissue type. However, in cancer tissues, there is a near
complete switch to isoform MSMB1, which is present at
96% total MSMB expression in prostate cancer. The ratio
of MSMB1:MSMB2 isoforms is altered from 0.02 [IQR
0.02]: 1 in BPH tissue to 25.7 [IQR 30.2]: 1 in prostate
adenocarcinoma tissues (P = 4.0 × 10-10, figure 4). In the
case of the HNF1B gene, coding for 3 isoforms, we noted
a similar switch in isoform expression. The predominant
isoforms in BPH samples is HNF1B(C), present at 90% of
total HNF1B expression. In prostate cancer tissues how-
ever, isoform HNF1B(B) is predominant at 95% total
HNF1B expression, with the levels of HNF1B(C) dropping
to only 3%. The proportion of isoform HNF1B(A) does
not change. The ratio of HNF1B(B):HNF1B(C) isoforms
changes from 0.7 [IQR 0.22]: 1 in BPH to 35.4 [IQR
124.71]: 1 in prostate cancer tissues (P = 2.9 × 10-9; figure
5). We also found 47% and 50% reductions in CTBP2(1)
and CTBP2(4) expression levels in prostate cancer tissue
compared with benign prostate tissues (P = 0.009 and
0.007 for CTBP2(1) and CTBP2(4) respectively), but these
values do not reach statistical significance following
adjustment for multiple testing (P = < 0.003 for 12 tests).
Previous exposure to antiandrogenic drugs did not affect
the ratio of MSMB or HNF1B splice variants in samples
from prostate cancer or BPH patients (P = 0.24 in
Figure 4 The ratio of alternatively-expressed isoforms of the MSMB gene is altered in prostate cancer tissues. This boxplot gives the cancer 
status (benign prostatic hyperplasia or prostate adenocarcinoma) on the X-axis, and the ratio of MSMB1:MSMB2 isoform expression calculated relative 
to endogenous controls beta-2-microglobulin (B2M) and beta-glucorinidase (GUSB) on the Y-axis. Error bars represent the interquartile range (IQR) of 
the measurements. The level of significance as determined by pairwise Mann Whitney-U analyses is indicated. Outliers are indicated by circles.
4.0 X 10-10
BPH Prostate cancer
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tate cancer cohort and P = 0.88 24 in untreated subjects
and 0.72 in treated subjects for the BPH cohort).
Discussion
We report here that disruption of the amount or nature of
transcripts expressed from the LMTK2, MSMB and
HNF1B genes, identified in the genome wide scans for
prostate cancer, may be important in the aetiology of this
disorder.
We identified a 68% reduction in the expression of the
LMTK2 gene in prostate tissue with evidence of the pres-
ence of adenocarcinoma when compared with non-
malignant BPH samples. Expression levels were 1.10 [IQR
0.77] in BPH versus 0.35 [IQR 0.30] in prostate cancer; p
= 3.2 × 10-7). We also noted an effect of genotype at the
LMTK2 variant rs6465657, identified in the GWAS as a
susceptibility factor for prostate cancer whereby individ-
uals carrying two alleles of the protective 'T' allele allelic
status expressed almost a third less LMTK2 than did indi-
viduals carrying one or more 'C' alleles (P = 0.002). We
suggest that this finding probably arises from a potential
imbalance in the transcription or stability of rs6465657
alleles that we note upon allele-specific PCR (figure 1).
The precise identity and mode of action of the functional
variant tagged by rs6465657 is at present unknown, but It
is reasonably easy to postulate that the 'C' allele at
rs6465657 could be marking a loss-of-function variant
with effects on LMTK2 half-life or function.
The LMTK2 gene codes for a transmembrane serine/
threonine/tyrosine kinase, with a role in endosomal
membrane trafficking [23]. It is also associated with
NGF-TrkA signalling in murine brain, where it is a nega-
tive regulator of NGF-induced neuronal differentiation
[24]. LMTK2 interacts negatively with several other pro-
teins with roles in cell division, such as protein phos-
phatase-1 (PP1C) and Inhibitor-2 (Inh2), which are part
of a complex regulating separation of centrosomes during
mitosis [25], and the cyclin-dependent kinase 5 (cdk5)/
p35 complex [26], which has several functions, including
a role in cell cycle progression. Recent studies have sug-
gested that LMTK2 may interact with myosin IV, which
has been shown to regulate both prostate specific antigen
(PSA) and vascular endothelial growth factor (VEGF)[27],
both of which are associated with cancer. It is therefore
likely that that reduction in the amount or activity of
LMTK2 may lead to an increase in the proliferative
capacity of prostate cells.
Figure 5 The ratio of alternatively-expressed isoforms of the HNF1B gene is altered in prostate cancer tissues. This boxplot gives the cancer 
status (benign prostatic hyperplasia or prostate adenocarcinoma) on the X-axis, and the ratio of HNF1B(B):HNF1B(C) isoform expression calculated rel-
ative to endogenous controls beta-2-microglobulin (B2M) and beta-glucorinidase (GUSB) on the Y-axis. Error bars represent the interquartile range 
(IQR) of the measurements. The level of significance as determined by pairwise Mann Whitney-U analyses is indicated. Outliers are indicated by circles.
2.9 X 10-9
BPH Prostate cancer
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processing of the HNF1B and MSMB genes in the aetiol-
ogy of prostate cancer. MSMB codes for a secreted semi-
noprotein, which has tumour suppressor properties and
is thought to be silenced in prostate tumour tissues by the
enhancer of zeste homolog 2 (EZH2) protein [28].
Accordingly, MSMB expression has previously been
reported to be a positive prognostic indicator in prostate
cancer [29], although both these studies measured total,
not isoform-specific expression levels. The MSMB gene
produces 2 isoforms; MSMB1 and MSMB2, which arise
from the skipping of exon 3 in MSMB2. This causes a
frameshift effect leading to the production of 2 distinct
proteins. Previous studies suggest that both MSMB1 and
MSMB2 are present in normal prostate and normal gas-
tric mucosa, but that MSMB2 is absent from the majority
of a small series of gastric and prostatic carcinomas [30].
This is mostly in agreement with our findings, which sug-
gest a major shift in MSMB expression in association with
prostate cancer. We found MSMB2 to be the predomi-
nant isoform in benign prostate tissue, although small
amounts (~2%) of MSMB1 were also present. In prostate
adenocarcinoma tissues, however, MSMB expression
derived almost completely from MSMB1, which is pres-
ent at 96% of total MSMB expression. These findings may
indicate that the tumour suppressor properties of MSMB
are derived from isoform MSMB2, and that MSMB1 iso-
forms are potentially pro-carcinogenic. This situation is
not uncommon for alternatively spliced genes in cancer;
the vascular endothelial growth factor (VEGF) gene has
previously been shown to code for both pro- and anti-
angiogenic isoforms, with different behaviours in tumour
tissues [16].
The HNF1B gene, which encodes three isoforms,
HNF1B(A), HNF1B(B) and HNF1B(C), in humans [31],
demonstrates a similar alteration to the relative balance
of alternatively expressed isoforms associated with cancer
of the prostate. The predominant isoform switches from
HNF1B(C), which is expressed in non-malignant prostate
tissues, to HNF1B(B) , which is expressed in prostate ade-
nocarcinoma samples. HNF1B is a transcription factor
expressed in a limited number of tissues, and has previ-
ously been associated with renal and ovarian tumours
[32,33] as well as prostate cancer [34]. The HNF1B iso-
forms are known to exhibit differences in function and
target specificities; Isoforms (A) and (B) are transcrip-
tional activators whereas isoform HNF1B(C) is a tran-
scriptional repressor [35]. HNF1B isoforms have also
been reported to activate different targets, for example,
the HNF1B(C) isoform specifically has been demon-
strated to negatively regulate the Glutahione-S-trans-
ferase A (GSTA) promoter, via a mechanism that involves
Il-1beta [36]. Given the difference in the transcriptional
properties and target specificity of these isoforms, we
predict that the alterations to HNF1B profile we note may
manifest as an alteration to the overall activity of the
HNF1B gene and/or activation of a variant set of its target
genes.
Our study provides good evidence that some of the
GWAS associations for prostate cancer may be attributed
to mRNA effects, but does have a number of caveats. We
have chosen a single gene for analysis in the case of each
GWAS variant. The variants may tag a large region con-
taining many genes, some of which may also be good can-
didates. Other genes in the same linkage disequilibrium
(D') blocks, or even further distant, could also be impor-
tant. This was recently documented for the eye colour
trait in humans, where variant rs12913832 located within
intron 86 of the HERC2 gene exerts its effects not by
moderating HERC2 activity, but by moderating the effi-
ciency of the promoter of the neighboring OCA2 gene,
located 21Kbp upstream [37]. We have attempted to
ensure we have chosen the correct gene on the basis of
proximity and biological function, but other genes may
also be affected. Our analysis was also based on compari-
son of samples from patients with prostate cancer, and
samples from patients with non-malignant Benign Pros-
tatic Hyperplasia (BPH), rather than a paired analysis due
to the difficulty in obtaining normal prostate tissue from
the cancer patients. Our results may thus be influenced
by factors both within and between groups, such as eth-
nic origin or the use of antiandrogenic drugs. No differ-
ences in the ethnic makeup of the cancer and control
cohorts were noted, with both being almost exclusively of
Caucasian origin. Similarly, treatment with antiandro-
gens had a minimal impact on the expression of any of the
transcripts studied; with the exception of CTBP2(1) and
CTBP2(4) transcripts, which showed a trend towards
lower expression in samples from prostate cancer
patients treated with hormone therapy, although this
result was not statistically significant and no correlations
of the expression of either transcript with hormone ther-
apy was noted in the BPH cohort. No effect of hormone
therapy on LMTK2 expression, or on the ratio of MSMB
or HNF1B transcripts was noted.
Conclusions
In this study, we suggest that the overall mRNA expres-
sion level and/or the relative balance of alternatively
expressed isoforms of the LMTK2, MSMB and HNF1B
genes may be important determinants in the develop-
ments of prostate cancer, and demonstrate the impor-
tance of alternative mRNA processing mechanisms such
as alternative splicing or differential use of polyadenyla-
tion sites in gene regulation. Our studies highlight a clear
need for RNA studies to complement the genome wide
association studies for prostate cancer and other diseases.
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